Suddenly, Wegovy sales are disappointing | CNN Business

London — Novo Nordisk trimmed its full-year profit outlook Wednesday after reporting weaker-than-expected quarterly sales of its popular weight loss drug Wegovy.

The results end a prolonged streak of positive earnings news from the first mover in the obesity drug race, which has seen its market value surge to more than $500 billion, making it Europe’s most valuable listed company.

Novo shares, which have soared some 230% since June 2021, fell as much as 7.7% in early trading and were down 4.8% by 9:21 a.m. ET.

Chief Financial Officer Karsten Munk Knudsen in an interview called the market reaction unsurprising, given the market’s sensitivity to

→ Continue reading at CNN - Business News

More from author

Related posts

Advertisment

Latest posts

Exclusive: Kevin O’Leary Is Launching a New Agency With the Founder of Shazam — Here’s Why He Says It’s a Game Changer

Multi-millionaire investor Kevin O'Leary has earned his nickname, Mr. Wonderful, after 15 seasons of dealmaking on "Shark Tank." Now, he's using that reputation to...

This Investment Strategy Will Help You Uncover Groundbreaking Opportunities That Traditional VCs Often Miss

Opinions expressed by Entrepreneur contributors are their own. In the changing landscape of venture capital, the once-sufficient generalist investment approach is facing...

Turn Trash Into Treasure — How Businesses Can Build Consumer Trust in the Booming Secondhand Market

Opinions expressed by Entrepreneur contributors are their own. As consumers worldwide embrace sustainability and economic savviness, the secondhand market is booming globally,...